The COVID-19 pandemic has significantly accelerated the adoption of decentralized clinical trials (DCTs), which allowed sponsors and CROs to quickly virtualize many trial activities, including remote monitoring, telehealth visits, electronic consent (eConsent), electronic patient reported outcomes (ePRO), electronic clinical outcome assessments (eCOA), and use of wearables/sensors. The uptake in DCTs is expected to continue in a post-COVID-19 world due to the experience gained during this time.

Download this white paper to read about the changing landscape around decentralized clinical trials, the types of solutions used to run DCTs, and how to reap the various benefits, such as:

• Enhanced patient experience
• Medicines delivered to market faster
• Greater time & cost efficiencies
• Convenience & reduced burden